Vaughn M. Kailian

Chairman of the Board, Cerimon
General Partner, MPM Capital
Vaughn M. Kailian was named Chairman of the Board of Cerimon Pharmaceuticals, Inc., in May, 2005. Additionally, Mr. Kailian serves as General Partner of MPM Capital. Mr. Kailian previously served as Vice Chairperson of the Board of Directors of Millennium Pharmaceuticals, Inc., and was head of the Millennium commercial organization, where he oversaw the integration of the COR Therapeutics, Inc. (COR) commercial organization, expanded the cardiovascular sales effort and led the establishment of the Millennium commercial group, which successfully launched VELCADE. Prior to joining Millennium, Mr. Kailian served from 1990 until 2002 as CEO, President, and Director of COR. He became the CEO of COR shortly after the company was founded, took the company public in 1991, raised almost $1 billion in public market capital, and led the merger with Millennium in 2002. Earlier in his career, Mr. Kailian held various international and U.S. general management, marketing, and sales positions at Marion Merrell Dow, Inc., and its predecessor companies, including President and General Manager, Merrell Dow USA, and Corporate Vice President of Global Commercial Development, Marion Merrell Dow, Inc. He is the Chairman of the Board of ViaCell, Inc. (Nasdaq: VIAC), Elixir Pharmaceuticals, Inc., and Ikaria, Inc. He is also a Director of NicOx, S.A., and Windhover Information, Inc. Mr. Kailian is currently a member of the Board of BIO Ventures for Global Health and the Pharmaceutical Foundation Advisory Council at the University of Texas at Austin. Mr. Kailian earned his BA degree at Tufts University.

Robert Adelman, MD

Principal, OrbiMed Advisors
Dr. Adelman joined OrbiMed Advisors in 2002 and specializes in private equity investments and structured transactions of small-capitalization public equity companies. Prior to OrbiMed, Dr. Adelman was Vice President of Business Development at NeoGenesis Pharmaceuticals, Inc., where he negotiated and closed several transactions. Before NeoGenesis, Dr. Adelman founded Veritas Medicine where he raised $11 million in venture funding. He also co-founded Operon Technology Inc., a company sold to Qiagen N.V. in 2000. Operon is one of the world’s largest commercial producers of synthetic DNA. Dr. Adelman trained as an orthopedic surgeon at the Hospital for Special Surgery at Cornell University. As a practicing orthopedic surgeon, he worked with major implant manufacturers on hip and knee replacement design, including Johnson and Johnson Orthopedics and Zimmer, Inc. Dr. Adelman earned his AB in biochemistry from the University of California, Berkeley and his MD from Yale University School of Medicine.

Ansbert Gadicke, MD

Founder, General Partner, MPM Capital
Dr. Ansbert Gadicke is the Founder and a General Partner of the MPM Group. He led MPM’s effort to build its Advisory and Investment Banking business from 1992 to 1996 and started its Asset Management business in 1996. Prior to founding MPM, Dr. Gadicke was employed by The Boston Consulting Group. Dr. Gadicke received an MD from J.W. Goethe University in Frankfurt. He subsequently held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT, Harvard University, and the German Cancer Research Center. He has published in leading scientific publications, including Nature and Cell. Dr. Gadicke is a Director of Arriva Pharmaceuticals, Inc., Cerimon Pharmaceuticals, Inc., Elixir Pharmaceuticals Inc., Omrix Biopharmaceuticals, Inc., Nuvios, Inc., Pharmasset, Inc., PharmAthene, Inc., and Xanodyne Pharmaceuticals, Inc. He previously served as a Director of BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), Coelacanth Corporation, Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), Kourion Therapeutics AG, MediGene AG (Frankfurt: MDG), Viacell, Inc. (Nasdaq: VIAC), and TransForm Pharmaceuticals, Inc. He is a member of Advisory Councils for Harvard Medical School and the Whitehead Institute at MIT. Dr. Gadicke serves as the Co-Chairman of the Alumni Association of the Whitehead Institute and serves on the Board of the National Venture Capital Association (NVCA).

Paul Hastings

President and Chief Executive Officer, OncoMed Pharmaceuticals
Paul Hastings is President and Chief Executive Officer of OncoMed. Prior, he was President, Chief Executive Officer and a Director of QLT, Inc. Before joining QLT in February 2002, Mr. Hastings was President, CEO, and a Director of Axys Pharmaceuticals, Inc., where he was responsible for leading the strategic acquisition of Axys by Celera Corporation. Since starting his career in 1984 with F. Hoffman-La Roche, Mr. Hastings has held various positions of increasing responsibility with notable biotech and pharmaceutical companies, including Vice President, Marketing and Sales and European General Manager, Synergen Inc.; Vice President, Global Marketing, Genzyme Corporation; President, Genzyme Therapeutics Europe; President, Genzyme Therapeutics Worldwide; and President, Chiron BioPharmaceuticals. Mr. Hastings holds a BS from the University of Rhode Island. He is also a member of several boards of directors including Viacell Inc. (Nasdaq: VIAC), Arriva Pharmaceuticals, Inc., and BC Leading Edge Endowment Fund.

Denise Pollard-Knight, PhD

Managing Director of Nomura Phase4 Ventures
Denise Pollard-Knight, PhD, is Managing Director of Nomura Phase4 Ventures, an affiliate of Nomura International plc. From January 1999 to March 2004, Dr. Pollard-Knight served as head of Healthcare Private Equity at Nomura International plc, a leading Japanese financial institution. Prior to joining Nomura, Dr. Pollard-Knight was a member of Rothschild Asset Management Ltd., an investment management firm, from January 1997 to January 1999. Dr. Pollard-Knight held several research and development management positions at Amersham-Pharmacia and Fisons plc. Dr. Pollard-Knight holds a PhD and BSc (Hons) from the University of Birmingham in England. Dr. Pollard-Knight completed post doctorate work as a Fulbright Scholar at the University of California, Berkeley. Dr Pollard-Knight currently serves on the Boards of Idenix Pharmaceuticals, ViaCell Inc, Nabriva Therapeutics and Develogen AG. She is currently a Trustee and a Council Member of the British Heart Foundation serving on the Executive Committee.

Paul Sekhri

Founder, President, and Chief Executive Officer
Paul Sekhri is the President and Chief Executive Officer of Cerimon Pharmaceuticals Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc., a Nasdaq-listed oncology company based in Cambridge, MA. In 2002 Mr. Sekhri joined Sprout Group, the venture affiliate of Credit Suisse First Boston in New York, where he was a Partner for healthcare technology investments. Prior to joining Sprout, Mr. Sekhri spent four years at Novartis, most recently as Senior Vice President and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. At Novartis, he was responsible for the creation of Novartis Pharmaceuticals’ Disease Area Strategy, as well as establishing a dedicated function focused on the identification and evaluation of new opportunities for the company. Prior to this, Mr. Sekhri set up a new department, Early Commercial Development, to ensure the differential competitive advantage of Novartis’ pipeline. Mr. Sekhri completed graduate work in neuroscience at the University of Maryland School of Medicine where he also received his BS in Zoology.

Mr. Sekhri is currently a member of the Board of Directors for Biodel Inc., based in Danbury, CT, and ARYx Therapeutics, a San Francisco-based pharmaceutical company, where he also serves as Chairman of the Compensation Committee. In addition, he is a member of the Advisory Board for The BioExec Institute, Inc., in Cambridge, MA. Mr. Sekhri also serves on the Board of Directors of the Irvington Institute for Immunological Research, a non-profit world leader in the funding of basic research in immunology. Mr. Sekhri is a Venture Partner with MPM Capital, one of the largest Venture Capital firms devoted to the life sciences.